BR0211178A - Cadeias nucleotìdicas quiméricas, proteìnas quiméricas, preparação farmacêutica, e, método diagnóstico - Google Patents

Cadeias nucleotìdicas quiméricas, proteìnas quiméricas, preparação farmacêutica, e, método diagnóstico

Info

Publication number
BR0211178A
BR0211178A BR0211178-0A BR0211178A BR0211178A BR 0211178 A BR0211178 A BR 0211178A BR 0211178 A BR0211178 A BR 0211178A BR 0211178 A BR0211178 A BR 0211178A
Authority
BR
Brazil
Prior art keywords
chimeric
proteins
chains
pharmaceutical preparation
diagnostic method
Prior art date
Application number
BR0211178-0A
Other languages
English (en)
Inventor
Lisset Hermida Cruz
Rayner Rodriguez Diaz
Laura Lazo Vazquez
Aida Zulueta Morales
Carlos Lopez Abarrategui
Iris Valdes Prado
Ricardo De La C Silv Rodriguez
Glay Chinea Santiago
Gerardo Enrique Guillen Nieto
Maria Guadalupe Guzman Tirado
Beatriz De La Caridad Vazquez
Raul Rafael Espinosa Perez
Original Assignee
Ct Ingenieria Genetica Biotech
Inst De Medicina Tropical Pedr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech, Inst De Medicina Tropical Pedr filed Critical Ct Ingenieria Genetica Biotech
Publication of BR0211178A publication Critical patent/BR0211178A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"CADEIAS NUCLEOTìDICAS QUIMéRICAS, PROTEìNAS QUIMéRICAS, PREPARAçãO FARMACêUTICA, E, MéTODO DIAGNóSTICO". Obtenção de cadeias quiméricas codificantes para proteínas que induzem no receptor efeitos contra vírus, as quais estimulam a produção de uma resposta humoral sorotipo-específica e proteção relativamente à infecção pelos vírus da Dengue, evitando-se os efeitos de amplificação viral sorotipo-inespecíficos causadores das hemorragias e complicações clinicas descritas neste tipo de patologia. Estas cadeias de ácidos nucléicos são compostas de uma combinação específica de fragmentos pertencentes ao gene de uma proteína mutante com atividade desidrogenase de N.meningitidis e fragmentos que codificam para uma região da proteína E do invólucro dos vírus da Dengue, as quais, ao serem inseridas em um vetor de expressão, dão como resultado as proteínas quiméricas com características específicas. As moléculas quiméricas resultantes desta invenção são aplicáveis na indústria farmacêutica na obtenção de preparações vacinais e diagnósticos de alta especificidade sorotípica para uso em humanos.
BR0211178-0A 2001-07-16 2002-07-12 Cadeias nucleotìdicas quiméricas, proteìnas quiméricas, preparação farmacêutica, e, método diagnóstico BR0211178A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20010172A CU23245A1 (es) 2001-07-16 2001-07-16 CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS
PCT/CU2002/000006 WO2003008571A2 (es) 2001-07-16 2002-07-12 Cadenas quiméricas codificantes para proteínas inductoras de efectos contra virus

Publications (1)

Publication Number Publication Date
BR0211178A true BR0211178A (pt) 2004-08-10

Family

ID=40091633

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0211178-0A BR0211178A (pt) 2001-07-16 2002-07-12 Cadeias nucleotìdicas quiméricas, proteìnas quiméricas, preparação farmacêutica, e, método diagnóstico

Country Status (18)

Country Link
US (4) US7279164B2 (pt)
EP (1) EP1418180B1 (pt)
JP (1) JP4417712B2 (pt)
KR (1) KR100991717B1 (pt)
CN (1) CN100378123C (pt)
AT (1) ATE349466T1 (pt)
BR (1) BR0211178A (pt)
CA (1) CA2453300C (pt)
CU (1) CU23245A1 (pt)
DE (1) DE60217129T2 (pt)
DK (1) DK1418180T3 (pt)
ES (1) ES2278041T3 (pt)
GT (1) GT200200150A (pt)
MX (1) MXPA04000486A (pt)
MY (1) MY138482A (pt)
PT (1) PT1418180E (pt)
WO (1) WO2003008571A2 (pt)
ZA (1) ZA200400289B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23245A1 (es) 2001-07-16 2007-10-17 Inst De Medicina Tropical Pedr CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS
CU23578A1 (es) * 2005-09-16 2010-09-30 Ct Ingenieria Genetica Biotech Proteína de la cápsida del virus dengue inductora de respuesta protectora y composición vacunal
CU23586A1 (es) 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
CU23630A1 (es) 2006-10-30 2011-02-24 Ct Ingenieria Genetica Biotech Moléculas peptídicas quiméricas con propiedades antivirales contra los virus de la familia flaviviridae
CU20080028A6 (es) * 2008-02-29 2011-02-24 Ct Ingenieria Genetica Biotech Compuestos químicos obtenidos in silico para la preparación de composiciones farmacéuticas para atenuar o inhibir la infección por virus dengue y otros flavivirus
EP2632485A4 (en) 2010-10-29 2014-05-28 Merck Sharp & Dohme RECOMBINANT SUBUNIT VACCINE AGAINST DENGUE VIRUS
CU24188B1 (es) * 2012-12-27 2016-07-29 Ct De Ingeniería Genética Y Biotecnología Composición vacunal contra el virus dengue
ITRM20130458A1 (it) * 2013-08-05 2015-02-05 Internat Ct For Genetic En Gineering And Vaccino genetico anti-dengue virus basato sugli ectodomini della proteina envelope
CN110343172B (zh) * 2018-04-04 2021-09-03 中国科学院微生物研究所 一种高灵敏度的黄热病毒人源单克隆抗体及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22302A1 (es) 1990-09-07 1995-01-31 Cigb Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales
ATE186744T1 (de) 1991-09-19 1999-12-15 Us Health Chimäre und/oder wachstumsgehemmte flaviviren
AU716676B2 (en) 1995-05-24 2000-03-02 Hawaii Biotech, Inc. Subunit vaccine against flavivirus infection
CU22559A1 (es) * 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
AU2933797A (en) 1996-05-10 1997-12-05 Schering Corporation Synthetic inhibitors of hepatitis c virus ns3 protease
CU22666A1 (es) 1996-11-25 2001-04-27 Inst De Medicina Tropical Pedro Kouri Procedimiento para la expresión de genes de los virus del dengue en la levadura pichia pastoris, adns recombinantes y microorganismos transformados
CU22683A1 (es) * 1997-01-15 2001-07-20 Inst De Medicina Tropical Pedro Kouri Epítopes de la proteína pre-m/m del virus del dengue, péptidos sintéticos, proteínas quiméricas y sus usos
ATE291032T1 (de) 1997-08-11 2005-04-15 Boehringer Ingelheim Ca Ltd Hepatitis c inhibitor peptide
RU2208635C2 (ru) 1997-10-08 2003-07-20 ЗЕ ГАВЕРМЕНТ ОФ ЗЕ ЮНАЙТЕД СТАЙТС ОФ АМЕРИКА, репрезентед бай ЗЕ СЕКРЕТЕРИ, ДЕПАРТМЕНТ ОФ ХЕЛС ЭНД ХЬЮМЭН СЕРВАЙСЕЗ Днк-конструкт жизнеспособного химерного рекомбинантного флавивируса, вакцина против вируса клещевого энцефалита, способ предотвращения инфицирования млекопитающего вирусом клещевого энцефалита
AU780308B2 (en) 1999-04-30 2005-03-17 J. Craig Venter Institute, Inc. Neisseria genomic sequences and methods of their use
CU23245A1 (es) 2001-07-16 2007-10-17 Inst De Medicina Tropical Pedr CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS
US20040259224A1 (en) * 2002-05-31 2004-12-23 Farshad Guirakhoo Tetravalent Dengue vaccines
AU2003300831A1 (en) 2002-12-11 2004-06-30 Hawaii Biotech, Inc. Recombinant vaccine against flavivirus infection
EP1454988A1 (en) 2003-03-03 2004-09-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Infectious flavivirus pseudo-particles containing functional prM-E envelope proteins
WO2005002501A2 (en) 2003-04-22 2005-01-13 Children's Medical Center Corporation Novel druggable regions in the dengue virus envelope glycoprotein and methods of using the same
WO2006078657A2 (en) 2005-01-19 2006-07-27 Vaxinnate Corporation Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response
CA2508266A1 (fr) 2005-06-20 2006-12-20 Institut Pasteur Polypeptides chimeriques et leurs applications therapeutiques contre une infection a flaviviridae
CU23632A1 (es) 2006-04-28 2011-02-24 Ct Ingenieria Genetica Biotech Métodos para la identificación de candidatos terapéuticos contra enfermedades causadas por flavivirus y moléculas antivirales.

Also Published As

Publication number Publication date
CU23245A1 (es) 2007-10-17
CN1531548A (zh) 2004-09-22
CA2453300A1 (en) 2003-01-30
US7566457B2 (en) 2009-07-28
EP1418180B1 (en) 2006-12-27
US20090274718A1 (en) 2009-11-05
WO2003008571A9 (es) 2004-04-15
ATE349466T1 (de) 2007-01-15
ES2278041T3 (es) 2007-08-01
MY138482A (en) 2009-06-30
WO2003008571A2 (es) 2003-01-30
CN100378123C (zh) 2008-04-02
DK1418180T3 (da) 2007-05-07
EP1418180A2 (en) 2004-05-12
US20070141081A1 (en) 2007-06-21
US7279164B2 (en) 2007-10-09
MXPA04000486A (es) 2005-03-07
GT200200150A (es) 2003-06-19
US8105606B2 (en) 2012-01-31
US20110200628A1 (en) 2011-08-18
CA2453300C (en) 2012-03-20
ZA200400289B (en) 2004-09-12
KR20040030056A (ko) 2004-04-08
JP4417712B2 (ja) 2010-02-17
US7947281B2 (en) 2011-05-24
DE60217129T2 (de) 2007-10-31
PT1418180E (pt) 2007-04-30
WO2003008571A3 (es) 2004-03-04
US20040234951A1 (en) 2004-11-25
JP2004537306A (ja) 2004-12-16
DE60217129D1 (de) 2007-02-08
KR100991717B1 (ko) 2010-11-03

Similar Documents

Publication Publication Date Title
US11497807B2 (en) Zoonotic disease RNA vaccines
US20230346914A1 (en) Sars-cov-2 mrna domain vaccines
US20230108894A1 (en) Coronavirus rna vaccines
US11696946B2 (en) Influenza vaccine
US20220323572A1 (en) Coronavirus rna vaccines
US20220202934A1 (en) Respiratory virus nucleic acid vaccines
Edery et al. Activation of double-stranded RNA-dependent kinase (dsl) by the TAR region of HIV-1 mRNA: a novel translational control mechanism
US11351242B1 (en) HMPV/hPIV3 mRNA vaccine composition
WO2021211343A1 (en) Zika virus mrna vaccines
Katz et al. Direct sequencing of the HA gene of influenza (H3N2) virus in original clinical samples reveals sequence identity with mammalian cell-grown virus
US20180312549A1 (en) High potency immunogenic compositions
WO2022067010A1 (en) Multi-proline-substituted coronavirus spike protein vaccines
WO2022221440A1 (en) Influenza-coronavirus combination vaccines
BR9914643A (pt) Vetores adeno-associados para expressão dofator viii por células alvo
JP2024514183A (ja) エプスタイン－バーウイルスｍＲＮＡワクチン
EP4355761A1 (en) Mrna vaccines encoding flexible coronavirus spike proteins
BR0211178A (pt) Cadeias nucleotìdicas quiméricas, proteìnas quiméricas, preparação farmacêutica, e, método diagnóstico
EP4308156A1 (en) Therapeutic use of sars-cov-2 mrna domain vaccines
WO2023196914A1 (en) Influenza nucleic acid compositions and uses thereof

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: C12N 15/00

Ipc: C12N 15/00 (2006.01), A61K 39/12 (2006.01), A61P 3

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 14A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.